We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-5.35%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.19B
AUM Growth
+$165M
Cap. Flow
+$307M
Cap. Flow %
25.82%
Top 10 Hldgs %
50.1%
Holding
72
New
19
Increased
15
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$40.2M
2
VERV
Verve Therapeutics
VERV
+$31.5M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$29.2M
4
LENZ
LENZ Therapeutics
LENZ
+$26.6M
5
IPSC icon
Century Therapeutics
IPSC
+$25.1M

Top Sells

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$21.6M
2
RPTX
Repare Therapeutics
RPTX
+$18.7M
3
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$10.1M
5
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$9.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PASG icon
51
Passage Bio
PASG
$15.3M
$1.66M 0.14%
6,251
– –
PRDS
52
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.23M 0.1%
123,543
-176,457
-59% -$1.77M
OBIO icon
53
Orchestra BioMed
OBIO
$229M
$1.02M 0.09%
100,000
-200,000
-67% -$2.07M
RACB
54
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$1.01M 0.09%
100,000
-200,000
-67% -$2.11M
DAWN
55
DELISTED
Day One Biopharmaceuticals
DAWN
$844K 0.07%
+37,069
New +$773K
MLTX icon
56
MoonLake Immunotherapeutics
MLTX
$1.66B
$518K 0.04%
50,000
-150,000
-75% -$1.52M
NUVB.WS
57
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$173K 0.01%
66,666
– –
MREO
58
Mereo BioPharma
MREO
$48.7M
$149K 0.01%
+46,984
New +$158K
BOLT icon
59
Bolt Biotherapeutics
BOLT
$7.8M
– –
-7,500
Closed -$4.94M
BTAI icon
60
BioXcel Therapeutics
BTAI
$26.7M
– –
-25,000
Closed -$17.3M
CNTB
61
Connect Biopharma Holdings
CNTB
$135M
– –
-150,000
Closed -$2.77M
HRMY icon
62
Harmony Biosciences
HRMY
$2.08B
– –
-100,000
Closed -$3.3M
KYMR icon
63
Kymera Therapeutics
KYMR
$9.09B
– –
-260,920
Closed -$10.1M
LRMR icon
64
Larimar Therapeutics
LRMR
$396M
– –
-230,000
Closed -$3.36M
SPRY icon
65
ARS Pharmaceuticals
SPRY
$563M
– –
-125,000
Closed -$5.45M
VRDN icon
66
Viridian Therapeutics
VRDN
$2.19B
– –
-550,000
Closed -$9.19M
VIRX
67
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-470,000
Closed -$4.35M
VINC
68
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-24,000
Closed -$9.26M
PNT
69
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-500,000
Closed -$5.25M
LHDX
70
DELISTED
Lucira Health, Inc. Common Stock
LHDX
– –
-250,000
Closed -$3.02M
EAR
71
DELISTED
Eargo, Inc. Common Stock
EAR
– –
-2,500
Closed -$2.5M
CEREW
72
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
– –
-33,333
Closed -$144K
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2021 Portfolio in Review

As of Q2 2021, Logos Global Management held 72 positions worth $1.19B, up 16% from $1.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Logos Global Management deployed $307M of net new capital in Q2 2021, opening 19 new positions and adding to 15 existing holdings. Its largest new stake was Verve Therapeutics: 758,265 shares worth $45.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $21.6M trimmed.

  • Logos Global Management's largest Q2 2021 buy was Verve Therapeutics: 758,265 shares worth $45.7M.
  • Logos Global Management added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $40.2M increase.
  • Logos Global Management's biggest Q2 2021 reduction was Dyne Therapeutics, cutting an estimated $21.6M.
  • Logos Global Management fully exited BioXcel Therapeutics in Q2 2021, selling an estimated $17.3M.
  • Logos Global Management's ten largest holdings make up 50% of its $1.19B portfolio in Q2 2021.
  • Logos Global Management opened 19 new positions and closed 14 in Q2 2021.
  • Logos Global Management's portfolio value rose 16% quarter-over-quarter to $1.19B.

Based on Logos Global Management's 13F filing for Q2 2021, filed 16 Aug 2021.